Health Care • Medical/Dental Instruments
$198.34 ▲ +3.18
(+1.63%)
MKT CAP: $54.03B • VOL: 2.20M
52W L $128 52W H $200
BDX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $21.84B | $20.18B | $19.37B |
| YoY Revenue Growth % | +8.2% | +4.2% | — |
| Gross Profit | $9.93B | $9.13B | $8.52B |
| Gross Margin % | 45.4% | 45.2% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.58B | $2.40B | $2.11B |
| Operating Margin % | 11.8% | 11.9% | 10.9% |
| Net Income (GAAP) | $1.68B | $1.71B | $1.48B |
| EBITDA (Normalized) | $3.19B | $2.98B | $2.81B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.88B | $1.91B | $1.66B |
| Capital Expenditures (CapEx) | $760.0M | $725.0M | $871.7M |
| Free Cash Flow (FCF) | $1.12B | $1.18B | $790.3M |
| FCF Margin % | 5.1% | 5.9% | 4.1% |
| Return on Invested Capital (ROIC %) | 4.9% | 4.5% | 9.3% |
| Cash & Short-Term Equivalents | $740.0M | $711.0M | $3.27B |
| Total Debt (Short + Long Term) | $16.92B | $17.44B | $6.95B |
| Total Stockholders' Equity | $25.28B | $25.20B | $14.26B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BDX.